**Supplementary Table 3**. Summary of oral NEPA antiemetic activity in patients with breast cancer receiving AC in clinical trials and in the real-world setting – multiple cycles of chemotherapy

|  |  |  |
| --- | --- | --- |
| **Study design** | **Pivotal randomized controlled trial** | **Real-world study** |
| **Chemotherapy** | **AC HEC [1,2]** **Cycles: 1/2/3** | **AC HEC [3,4]** **Cycles: 1/2/3** | **AC HEC** **Cycles: 1/2/3** |
| **Outcome, %** | **NEPA + DEX (n = 708/621/586)** | **NEPA + DEX****(n = 202/198/157)** | **NEPA + DEX\***,†,‡ |
| **CR**AcuteDelayedOverall | 88.3/89.9/91.676.4/81.5/85.073.9/80.0/83.6 | 88.6/-/-78.7/-/-77.2/81.3/83.4 | 86.0/86.9/88.388.2/87.2/86.081.0/81.7/81.1 |
| **No emesis** AcuteDelayedOverall | 90.8/-/-81.4/-/-79.5/-/- | 92.6/-/-87.1/-/-86.1/90.4/89.2 | 94.2/95.1/96.297.1/96.7/96.992.8/93.5/94.4 |
| **NSN** AcuteDelayedOverall | 87.0/88.7/88.976.6/79.2/79.574.2/77.0/78.2 | 85.1/-/-77.2/-/-74.8/73.2/80.9 | 69.1/73.9/76.072.7/71.5/70.160.1/61.8/62.4 |

\*Number of evaluable patients for CR in cycles 1/2/3 by phase: acute, 1120/1092/1047; delayed, 1093/1067/1023; overall, 1075/1055/1023.
†Number of evaluable patients for no emesis in cycles 1/2/3 by phase: acute, 1120/1092/1047; delayed, 1093/1067/1023; overall, 1075/1055/1013.
‡Number of evaluable patients for NSN in cycles 1/2/3 by phase: acute, 1130/1102/1057; delayed, 1119/1093/1044; overall, 1103/1085/1038.
AC, anthracycline plus cyclophosphamide; CR, complete response; DEX, dexamethasone; HEC, highly emetogenic chemotherapy; NEPA, netupitant (300 mg) and palonosetron (0.50 mg); NSN, no significant nausea; PALO, palonosetron.

**Supplementary references:**

1. Aapro M and Schwartzberg L. Efficacy of intravenous (IV) NEPA and oral NEPA, fixed NK1/5-HT3 receptor antagonist combination agents, for prevention of chemotherapy-induced nausea and vomiting following anthracycline-cyclophosphamide (AC)-based chemotherapy. San Antonio Breast Cancer Symposium. 2019. Poster P2-12-04.
2. Rugo HS, Rossi G, Rizzi G, et al. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. Breast. 2017;33:76–82.
3. Schwartzberg, L., Voisin, D., Rizzi, G., Patel, K., Aapro, M., 2019. Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients with breast cancer receiving anthracycline/cyclophosphamide (AC) chemotherapy. Support. Care Cancer 27 (Suppl 1):abstract eP023.
4. Schwartzberg L, Navari R, Clark-Snow R, et al. Phase 3b safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline/cyclophosphamide (AC) chemotherapy. The Oncologist. 2020;25(3):e589–e597.